Fathi, A. T., Lin, W. M., Durazzo, T., Piris, A., Sadrzadeh, H., Bernardo, L., … Chen, Y.-B. (2016). Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia. J Clin Oncol, 34(8), e70–e72. https://doi.org/10.1200/JCO.2013.50.7582

Fathi, Amir T., William M. Lin, Tyler Durazzo, Adriano Piris, Hossein Sadrzadeh, Lindsay Bernardo, Darrel R. Borger, Steven L. McAfee, Daniela Kroshinsky, and Yi-Bin Chen. “Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.” J Clin Oncol 34, no. 8 (March 10, 2016): e70–72. https://doi.org/10.1200/JCO.2013.50.7582.

Fathi AT, Lin WM, Durazzo T, Piris A, Sadrzadeh H, Bernardo L, et al. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia. J Clin Oncol. 2016 Mar 10;34(8):e70–2.

Fathi, Amir T., et al. “Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.” J Clin Oncol, vol. 34, no. 8, Mar. 2016, pp. e70–72. Pubmed, doi:10.1200/JCO.2013.50.7582.

Fathi AT, Lin WM, Durazzo T, Piris A, Sadrzadeh H, Bernardo L, Borger DR, McAfee SL, Kroshinsky D, Chen Y-B. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia. J Clin Oncol. 2016 Mar 10;34(8):e70–e72.